Peptide And Oligonucleotide CDMO Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the peptide and oligonucleotide cdmo market?
In recent years, the size of the peptide and oligonucleotide cdmo market has experienced significant expansion. The market is projected to increase from $2.16 billion in 2024 to $2.42 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.1%. The growth observed in the historical period was driven by an amplified demand for therapeutic agents, advancements made in synthesis and manufacturing processes, rising trend of personalized medicine, regulatory directives, and a heightened focus on antiviral peptides and mRNA vaccines, underlining the promise held by oligonucleotides in the field of vaccine development.
What will be the peptide and oligonucleotide cdmo market size in the future?
In the forthcoming years, a swift expansion is predicted for the peptide and oligonucleotide cdmo market, with its size projected to reach $3.79 billion by 2029 at a compound annual growth rate (CAGR) of 11.9%. The surge in the predicted period can be ascribed to the rising demand for customized medicine, biotechnology progression, broadening uses, escalating outsourcing, and an increasing load of chronic illnesses. Foreseen trends for the projected period encompass individualized therapies, technological progression, quality control difficulties, worldwide proliferation, and heightened cooperation amongst biopharmaceutical firms.
Get your peptide and oligonucleotide cdmo market report here!
What main drivers are fueling expansion in the peptide and oligonucleotide cdmo market?
The escalating uptake of personalized medicine is set to amplify the expansion of the peptide and oligonucleotide CDMO markets in the future. Personalized medicine refers to a healthcare strategy that customizes medical actions and treatments based on unique individual aspects such as genetics, environment, and lifestyle. The surging uptake of personalized medicine is attributed to various elements like the advancement in genomic technologies, an enhanced comprehension of disease processes at the molecular level, as well as the demand for more efficient and focused treatment methods customized to patients’ genetic profiles and medical histories. In the sphere of personalized medicine, peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) hold a vital position by manufacturing custom-made therapeutic peptides and oligonucleotides specified to individual patient requirements. For example, in February 2024, as per the Personalized Medicine Coalition, a UK-based entity that advocates for personalized medicine adoption, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) gave the green light to 16 new personalized treatments for patients suffering from rare diseases, an increase from 6 in 2022. Hence, the escalating adoption of personalized medicine is propelling the growth of the peptide and oligonucleotide CDMO market.
What key areas define the segmentation of the global peptide and oligonucleotide cdmo market?
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp
Who are the dominant players expanding their reach in the peptide and oligonucleotide cdmo market?
Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
What are the key trends shaping the future of the peptide and oligonucleotide cdmo market?
Leading firms in the peptide and oligonucleotide CDMO market are concentrating on forging strategic alliances to bolster their service portfolio, advance their technological prowess, and widen their market footprint. Collaborations for peptide development and production typically involve two entities focusing on the creation and fabrication of peptide-based treatments. For example, the US-based CDMO, PolyPeptide Group AG, entered into a strategic alliance with the German biotechnology firm Numaferm GmbH in May 2023. The partnership’s objective is to leverage PolyPeptide’s cGMP manufacturing capabilities and market penetration, coupled with Numaferm’s proficiency in sustainable peptide production and biochemical manufacturing platforms. This joint venture concentrates on the shared exploration of suitable peptide possibilities with the overarching objective of more environmentally-friendly peptide-based API production.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15892
Which regions are emerging as leaders in the peptide and oligonucleotide cdmo market?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Biosimilar Therapeutic Peptides Global Market Report 2024
Glucagon-like Peptide 1 Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report
Cell Penetrating Peptide Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cell-penetrating-peptide-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
